[Visual analysis of research status and frontier trend of Panlongqi Tablets].

Authors

Jia-Lin Wang, Xiao-Xuan Li, Qian-Qian Yan, Qing-Yu Zhao, Li-Ting Xu, Li-Li Wang, Teng-Fei Han, Chun-Fang Liu, Na Lin

Published in

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. Volume 51. Issue 17. Pages 4817-4826.

Abstract

Through bibliometrics and CiteSpace visualization software, this study explored the hot spots and directions of research on the Chinese medicine compound Panlongqi Tablets, providing directions for related research. The databases of CNKI, Wanfang, VIP, Sino Med, and Web of Science were searched. CiteSpace 6. 3 R1 software was used for visual analysis of the relevant literature on Panlongqi Tablets from the establishment of these databases to January 8, 2025. Finally, 160 pieces of literature on Panlongqi Tablets were included, mainly clinical papers. Panlongqi Tablets were recommended by nine guidelines and had six invention patents. There are multiple publishing teams and institutions, with the team of ZHANG De-zhu and LIN Na having the largest number of publications(five papers each). Shaanxi Panlong Pharmaceutical Group Limited by Share LTD. and China Academy of Chinese Medical Sciences are the main publishing institutions, and there is less cooperation between different authors and institutions. In terms of keyword analysis, the main keywords are " controlled study" " fracture" " rheumatoid arthritis" " osteoarthritis" " Meta-analysis" " network pharmacology", and so on. A total of 19 clusters were obtained, which were grouped into four cluster themes: clinical research, pharmacological experiments, chemical components, and safe drug use. The current focus is mainly on the evaluation of clinical efficacy and pharmacological effects of osteoarthritis, fracture, and other orthopedic diseases, the determination of effective components of Panlongqi Tablets, and drug safety. Future research can combine multidisciplinary technology and artificial intelligence to fully explore the clinical characteristics and advantages of the " Qi yao" represented by Panlongqi Tablets, expand the indications, and complete a clearer definition of safety.

PMID:
42869788
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.